|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.00 USD | +0.64% |
|
-1.12% | +78.86% |
| Jul. 09 | Immucell Corporation Reports Preliminary Unaudited Sales Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| May. 15 | ImmuCell Corporation, Q1 2026 Earnings Call, May 15, 2026 |
Business description: ImmuCell Corporation

Number of employees: 73
Sales by Activity: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Scours | - | 18.41M | 17.29M | 26.31M | 27.45M |
Mastitis | - | 155K | 178K | 179K | 196K |
Biotechnology | 19.24M | - | - | - | - |
Other | - | 1.46K | - | - | - |
Geographical breakdown of sales: ImmuCell Corporation
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 16.62M | 17.02M | 15.95M | 22.89M | 24.39M |
Other | 2.62M | 1.55M | 1.52M | 3.6M | 3.25M |
Executive Committee: ImmuCell Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 2025-10-31 | |
Timothy Fiori
DFI | Director of Finance/CFO | 47 | 2025-04-06 |
| Comptroller/Controller/Auditor | - | - |
Composition of the Board of Directors: ImmuCell Corporation
| Director | Title | Age | Since |
|---|---|---|---|
David Tomsche
CHM | Chairman | 69 | 2013-11-30 |
Paul Wainman
BRD | Director/Board Member | 61 | 2014-03-30 |
Gloria Basse
BRD | Director/Board Member | 66 | 2020-06-09 |
| Director/Board Member | 54 | 2025-10-31 | |
Kathy Turner
BRD | Director/Board Member | 62 | 2026-03-31 |
| Director/Board Member | 64 | 2026-04-14 | |
Anthony DiMarco
BRD | Director/Board Member | 63 | 2026-04-14 |
Company details: ImmuCell Corporation

Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.64% | -1.12% | +62.72% | +108.33% | 98.88M | ||
| +0.62% | +1.37% | +48.40% | +160.22% | 1,057B | ||
| +1.41% | +3.85% | +54.98% | +53.60% | 624B | ||
| +0.51% | +1.56% | +35.43% | +80.51% | 454B | ||
| +1.60% | +6.25% | +33.95% | +29.84% | 341B | ||
| -0.60% | +1.52% | +35.68% | +39.76% | 297B | ||
| -0.14% | +0.60% | +16.17% | +17.53% | 262B | ||
| +0.09% | -2.82% | -28.29% | -41.71% | 215B | ||
| +1.14% | +2.64% | +21.85% | +59.70% | 201B | ||
| -0.83% | -3.20% | +14.82% | +67.37% | 162B | ||
| Average | +0.57% | +0.52% | +29.57% | +57.51% | 361.41B | |
| Weighted average by Cap. | +0.70% | +1.57% | +35.61% | +77.46% |
- Stock Market
- Stocks
- ICCC Stock
- Company ImmuCell Corporation
Select your edition
All financial news and data tailored to specific country editions

















